Investigational drug · Phase 2
GI-102
Not approved by FDA. In 2 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Advanced Solid Tumor, Metastatic Solid Tumor, Soft Tissue Sarcoma (STS).
Phase 2Last checked: Nov 19, 2026Latest source record: Nov 9, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
2
2 still active
All registered trials
3
Any phase or sponsor naming "GI-102"
First trial start
2023
May 30, 2023
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "GI-102", any sponsor or status.
Conditions studied
As listed on its trial records.
- Advanced Solid Tumor
- Metastatic Solid Tumor
- Soft Tissue Sarcoma (STS)
- Platinum-resistant Ovarian Cancer (PROC)
- Hepatocellular Carcinoma (HCC)
- Colorectal Cancer (CRC)
- HER2 Negative Breast Cancer
- Cutaneous Melanoma
- Renal Cell Carcinoma (RCC)
- Metastatic Castration-resistant Prostate Cancer (mCRPC)
Approved drugs for the same conditions: Breast cancer · Prostate cancer · Colorectal cancer · Melanoma · Ovarian cancer · Kidney cancer (renal cell carcinoma) · Oncology · Kidney and urology
Largest trials
Live from ClinicalTrials.gov: studies naming "GI-102" as an intervention, largest first.
GI Innovation, Inc.Industry
NCT05824975 · 358 participants (planned) · Start May 30, 2023 · Primary completion Nov 12, 2025
Drug: GI-102 subcutaneous (SC); GI-102 and 7 more · For: Advanced Solid Tumor; Metastatic Solid Tumor; Soft Tissue Sarcoma (STS) and 6 more
Sites: Scottsdale, Arizona; Jacksonville, Florida; Rochester, Minnesota · 11 sites in all
GI Innovation, Inc.Industry
NCT07871435 · 107 participants (planned) · Start Oct 12, 2026 · Primary completion Mar 31, 2029
Drug: GI-102; Pasritamig · For: Metastatic Castration-resistant Prostate Cancer (mCRPC)
Sites: New York, New York; Seoul, South Korea · 6 sites in all
Mayo ClinicAcademic, hospital or other
NCT07301268 · 36 participants (planned) · Start Aug 3, 2026 · Primary completion Sep 1, 2029
Drug: Bispecific CD80-lgG4Fc-IL-2v Fusion Protein GI-102; Pembrolizumab · For: Glioblastoma, IDH-Wildtype; Progressive Astrocytoma, IDH-Mutant, Grade 4; Progressive Glioblastoma and 6 more
Sites: Rochester, Minnesota
Newest research
PubMed records naming it or its code names, newest first.
- Correlation of induction of ATP binding cassette transporter A5 (ABCA5) and ABCB1 mRNAs with differentiation state of human colon tumor.
Ohtsuki S, Kamoi M, Watanabe Y, et al. · Biol Pharm Bull 2007
- Isolation and characterization of a novel human NM23-H1B gene, a different transcript of NM23-H1.
Ni X, Gu S, Dai J, et al. · J Hum Genet 2003
- Cloning and identification of a cDNA that encodes a novel human protein with thrombospondin type I repeat domain, hPWTSR.
Chen JZ, Wang S, Tang R, et al. · Mol Biol Rep 2002
Also in development for Advanced Solid Tumor
- I-DXdDS-7300a, MK-2400Phase 317 trials
Merck & Co. · Small Cell Lung Cancer, Carcinoma, Non-Small-Cell Lung, Esophageal Squamous Cell Carcinoma
- HS-20093Ris-Rez, Risvutatug rezetecanPhase 316 trials
Hansoh BioMedical R&D Company · Neoplasms, Lung, Sarcoma, Osteosarcoma
- LBL-024Phase 311 trials
Nanjing Leads Biolabs Co.,Ltd · Advanced Solid Tumour, Advanced Extrapulmonary Neuroendocrine Carcinoma, Metastatic Colorectal Carcinoma
- TQB2102Phase 311 trials
Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. · Breast Cancer, HER2-positive Breast Cancer, Gynecological Tumors
- YL201Tambotatug Pelitecan, Tam-PeliPhase 311 trials
MediLink Therapeutics (Suzhou) Co., Ltd. · Advanced Solid Tumor, Small Cell Lung Cancer, Metastatic Pancreatic Cancer
- ZG005Phase 311 trials
Suzhou Zelgen Biopharmaceuticals Co.,Ltd · Advanced Solid Tumor, Lymphoma, Non-small Cell Lung Cancer
- R-DXdDS 6000a, MK-5909Phase 310 trials
Merck & Co. · Fallopian Tube Cancer, Ovarian Cancer, Peritoneal Cancer
- QLC5508MHB088CPhase 39 trials
Qilu Pharmaceutical Co., Ltd. · Advanced/Metastatic Solid Tumors, Advanced Malignant Solid Tumor, Extrapulmonary Neuroendocrine Carcinoma
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.